| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Immunology, Research Institute of Scripps Clinic, La Jolla, California 92037 [E. B., B. M. M., R. A. R.]; Department of Hematology, Children's Hospital, University of Tübingen, D-7400 Tübingen, [R. H., M. H.] Federal Republic of Germany; and Department of Pediatrics, University of California Medical Center, San Diego, California 92103 [A. L. Y.]
An anti-GD2 ganglioside human/mouse chimeric monoclonal antibody, ch14.18, like its murine counterpart, 14.G2a, was shown to bind to human neuroblastoma cells. This chimeric antibody proved to be more effective than 14.G2a in mediating the lysis of neuroblastoma cells with human effector cells, such as granulocytes and natural killer cells within the peripheral blood mononuclear cell population. A comparison of these two effector cell populations isolated from the same donor revealed granulocytes to be more effective than peripheral blood mononuclear cells in lysing neuroblastoma cells, which were coated with monoclonal antibody ch14.18. Addition of recombinant human granulocyte-macrophage colony-stimulatory factor increased ch14.18-mediated lysis of neuroblastoma cells by granulocytes but not by peripheral blood mononuclear cells. In fact, granulocytes were effective in mediating lysis of neuroblastoma cells coated with ch14.18 irrespective of whether they were obtained from normal adults or from neuroblastoma patients.
1 The work was supported by NIH Grant CA42508. This is the Research Institute of Scripps Clinic's Manuscript 6470IMM.
2 To whom requests for reprints should be addressed, at Department of Immunology, IMM13, Research Institute of Scripps Clinic, 10666 N. Torrey Pines Road, La Jolla, CA 92037.
Received 8/ 8/90. Accepted 10/ 9/90.
This article has been cited by other articles:
|
|
 |
|
  N.-K. V. Cheung, R. Sowers, A. J. Vickers, I. Y. Cheung, B. H. Kushner, and R. Gorlick FCGR2A Polymorphism Is Correlated With Clinical Outcome After Immunotherapy of Neuroblastoma With Anti-GD2 Antibody and Granulocyte Macrophage Colony-Stimulating Factor J. Clin. Oncol., June 20, 2006; 24(18): 2885 - 2890. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. R. Watkins and S. F. Maier Beyond Neurons: Evidence That Immune and Glial Cells Contribute to Pathological Pain States Physiol Rev, October 1, 2002; 82(4): 981 - 1011. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Rossig, C. M. Bollard, J. G. Nuchtern, C. M. Rooney, and M. K. Brenner Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy Blood, March 15, 2002; 99(6): 2009 - 2016. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. H. Kushner, K. Kramer, and N.-K. V. Cheung Phase II Trial of the Anti-GD2 Monoclonal Antibody 3F8 and Granulocyte-Macrophage Colony-Stimulating Factor for Neuroblastoma J. Clin. Oncol., November 15, 2001; 19(22): 4189 - 4194. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. Engler, C. Thiel, K. Förster, K. David, R. Bredehorst, and H. Juhl A Novel Metastatic Animal Model Reflecting the Clinical Appearance of Human Neuroblastoma: Growth Arrest of Orthotopic Tumors by Natural, Cytotoxic Human Immunoglobulin M Antibodies Cancer Res., April 1, 2001; 61(7): 2968 - 2973. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. Batova, A. Kamps, S. D. Gillies, R. A. Reisfeld, and A. L. Yu The Ch14.18-GM-CSF Fusion Protein Is Effective at Mediating Antibody-dependent Cellular Cytotoxicity and Complement-dependent Cytotoxicity in Vitro Clin. Cancer Res., December 1, 1999; 5(12): 4259 - 4263. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
